NCCN Pharmacy Updates: Updates in the Treatment of Pancreatic Adenocarcinoma
Systemic therapy options in metastatic pancreatic cancer are evolving, including increasing usage of maintenance therapies. There is a need to review the current landscape of treatment regimens and have an understanding of their place in therapy.
Category
  • Pancreatic Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date March 11, 2021
NCCN Pharmacy Updates: Updates on Targeted Therapy in the Treatment of Metastatic Colorectal Cancer
Systemic therapy options in metastatic CRC are continuously evolving and new treatments are becoming available with utilization of various biomarkers. There is a need to review the current landscape of treatment regimens and have an understanding of their place in therapy.
Category
  • Colorectal Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date April 6, 2021
NCCN Pharmacy Updates: New Developments in the Management of Metastatic Bladder Cancer
In order to help patients make informed treatment decisions, health care professionals need to understand the clinical data regarding the indications and efficacy of novel therapies.
Category
  • Bladder Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date May 11, 2021
NCCN Pharmacy Updates: Novel Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.
Category
  • Multiple Myeloma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date June 9, 2021
NCCN Pharmacy Updates: Emerging Strategies for Pediatric Hodgkin Lymphoma Treatment
It is important for pharmacists to understand the long-term side effects of both systemic treatment and radiation in order to provide in-depth patient counseling, as well as appropriate therapy recommendations to the multidisciplinary team.
Category
  • Hodgkin Lymphoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date June 23, 2021
Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Management of Pediatric Aggressive Mature B-Cell Lymphoma
Clinicians who treat pediatric BL and DLBCL need to be informed about the recommendations in the new NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas so that they can appropriately stratify patients into risk groups, plan initial therapy, and manage common supportive care issues. They also need information on recommended surveillance protocols and treatment of relapsed/refractory disease.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Pharmacy Updates: New Agents for Soft Tissue Sarcoma and Gastrointestinal Stromal Tumors
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of novel treatments for soft tissue sarcomas and gastrointestinal stromal tumors.
Category
  • Soft Tissue Sarcomas
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date February 15, 2021
New NCCN Guidelines for Pediatric Cancers: Multidisciplinary Management of Wilms Tumor (Nephroblastoma)
The NCCN Guidelines for Wilms tumor (nephroblastoma) are new guidelines that will address management of favorable histology Wilms tumor in children. Treatment needs to be carefully selected to maximize cure and minimize long-term toxicities, such as renal failure, cardiac toxicity, and hypertension, because these children with favorable histology Wilms tumor generally have long-term survival if they receive appropriate management.
Category
  • Wilms Tumor (Nephroblastoma)
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date February 19, 2021
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
This tumor board will discuss how to select the most appropriate therapy for patients with lung cancer using a case-based format.
Category
  • Lung Cancers
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date February 24, 2021
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Cutaneous T-Cell Lymphomas
A multidisciplinary team approach involving hematology/oncology, dermatology, and radiation oncology is optimal for the management of patients with MF and SS, particularly those with advanced disease. Informing clinicians about the recommendations outlined in the NCCN Guidelines for Primary Cutaneous Lymphomas for the diagnosis and treatment of MF and SS can help them to develop an individualized treatment plan to improve quality of life and clinical outcomes.
Category
  • T-Cell Lymphomas
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date April 27, 2021